|
© 2002 American Academy of Neurology Brief Communications Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patientsFrom the Universitätsklinik für Neurologie (Drs. Almer and Deecke), Allgemeines Krankenhaus der Stadt Wien, and the Department of Clinical Pharmacology (J. Halaschek–Wiener), University of Vienna, Austria; Departments of Neurology (Drs. Almer, Teismann, and Przedborski) and Pathology (Dr. Przedborski), Columbia University, New York, NY; and Institute of Neurology (Drs. Stevic and Kostic), Clinical Center of Serbia, Belgrade, Yugoslavia. Address correspondence and reprint requests to Dr. Serge Przedborski, Departments of Neurology and Pathology, BB-307, Columbia University, 650 West 168th Street, New York, NY 10032; e-mail: SP30{at}Columbia.edu Levels of the potent pro-inflammatory prostaglandin E2 (PGE2) are elevated in postmortem spinal cords from patients with ALS, and inhibition of a key PGE2-synthesizing enzyme, cylcooxygenase-2, is neuroprotective in an in vitro model of ALS. The authors report that 82% of the patients with ALS studied had 2 to 10 times higher PGE2 levels in CSF compared with normal control subjects. That affected areas of the CNS are inflamed in ALS supports this. CSF PGE2 measurement may be useful in monitoring treatment for ALS. This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||
